French government plans new sick leave rules sparking public sector backlash

The French government plans to implement a three-day waiting period for sick leave in the civil service, reducing compensation to 90% after the first three days, aiming to save 1.2 billion euros. This move has sparked outrage among public employee unions, who argue it undermines civil servants' rights and purchasing power. The government justifies the changes by citing the need to align public sector practices with the private sector, where absenteeism rates are lower.

vpbank reports strong growth and strategic partnerships in third quarter results

VPBank reported a consolidated pre-tax profit of nearly VND 13.9 trillion for the first nine months of 2024, marking a 67% increase year-on-year. The bank's capital adequacy ratio stands at 15.7%, and it has successfully optimized its operations through digitalization, maintaining a low bad debt ratio below 3%. Strategic partnerships, including collaborations with Lotte C&F and BYD, are enhancing its market presence, particularly in the FDI segment.
17:32 28.10.2024

Hermès shares rise as UBS raises price target and maintains buy rating

Hermès shares rose 1% today, marking a third consecutive day of growth, following a positive recommendation from UBS. The firm raised its price target from €2,390 to €2,515, indicating a potential upside of 21%, while the luxury brand reported strong double-digit growth in the third quarter across most regions.
17:20 28.10.2024

Hermès shares rise as UBS boosts price target and maintains buy rating

Hermès shares rose 1% today, marking a third consecutive session of growth, driven by UBS's positive recommendation. The firm raised its price target from €2,390 to €2,515, indicating a potential upside of 21%. The luxury brand reported strong double-digit growth in Q3, with all regions performing well except for APAC (excluding Japan).
17:15 28.10.2024

Hermès stock rises as UBS raises price target and maintains buy rating

Hermès shares have gained 3% over three consecutive sessions, boosted by UBS's positive recommendation, which raised the price target from €2,390 to €2,515, indicating a potential upside of 21%. The luxury brand reported strong double-digit growth in Q3, with all regions performing well except for APAC (excluding Japan).
17:15 28.10.2024

aeromexico launches 1.1 billion debt offering to refinance 2027 notes

Grupo Aeromexico SAB is seeking to raise up to $1.1 billion in the private debt market to refinance notes maturing in 2027. The airline is offering five-year and seven-year notes, with pricing expected to occur on Monday, according to an anonymous source.

ubs share price rises amid strong trading volume and positive earnings outlook

UBS shares rose by 0.3% to CHF 27.95, with a daily high of CHF 28.06, amidst a SMI trading at 12,243 points. The stock's 52-week high is CHF 28.78, while the low is CHF 21.07. UBS reported Q2 earnings of CHF 0.32 per share and revenue of CHF 19.76 billion, a 38.06% increase year-over-year.
17:08 28.10.2024

drug stocks poised for earnings surprises in third quarter results

The third-quarter earnings season for major drugmakers, including Pfizer, Eli Lilly, AbbVie, Merck, and Bristol Myers Squibb, is underway, with Pfizer expected to report results on Oct. 29. Pfizer has consistently exceeded earnings expectations, with a four-quarter average surprise of 69.82%, despite declining COVID product sales. Overall, the Medical sector anticipates a 3.5% year-over-year earnings increase and an 8.8% revenue growth.

Archy secures 15 million funding to enhance AI-driven dental practice automation

Archy has secured $15 million in Series A funding, led by Entrée Capital, to enhance its AI-driven, cloud-based automation platform for dental practices. The investment aims to address staffing shortages, outdated systems, and declining insurance reimbursements, enabling practices to improve efficiency and patient care. With this funding, Archy plans to integrate more AI and machine learning features, further streamlining operations for hundreds of dental practices across the US.

abbvie acquires aliada therapeutics for 1.4 billion to enhance neuroscience portfolio

AbbVie has agreed to acquire Aliada Therapeutics for $1.4 billion, gaining access to innovative drug delivery technology aimed at overcoming the blood-brain barrier and a clinical-stage Alzheimer’s treatment, ALIA-1758. This move aligns with AbbVie’s focus on neuroscience, enhancing its capabilities in developing therapies for neurological disorders. The deal is expected to close by year-end and reflects a strategic investment in a sector facing challenges but also potential breakthroughs.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings